High-impact quarter for Neurotech International
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Neurotech International (ASX:NTI), developer of quality medical solutions aimed at improving the lives of children with autism, has released its quarterly activities for the period ending June 30 2018, reporting strong progress.
Following provisional acceptance of the US clinical trial for Mente Autism by leading medical journal, Frontiers in Neurology in June, NTI recently revealed that full results of the trial had been published. Confirming the positive impact of Mente Autism for children with autism spectrum disorder (ASD), these results showed significant changes in the active treatment group, including:
- Significant reductions in the brain wave frequency bands of interest, delta, beta and high beta, which are typically abnormally high in children with autism
- Improved balance with eyes open rather than closed, which is the opposite effect experienced by autistic children
- Positive effects and a reduction of autistic behaviors across questionnaires used globally as validated tools in clinical applications
- Parents indicating significant improvements in social skills and communication of their children
In June, NTI also announced CE acceptance of considerable improvements to Mente Autism, enabling the company to move ahead with production. These include improvements to wi-fi connectivity, synchronisation and usability linked to the firmware and the Mente Autism application.
As always, it should be noted that NTI is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.
A bit more on NTI’s successful US clinical trial
The clinical trial, which was carried out by Florida's Carrick Institute, was a randomised-controlled, double-blind investigation that compared Mente Autism with a control (or sham) device over 12 weeks.
This trial was designed to ascertain the consequences of the Mente Autism neurofeedback treatment, with a variety of outcome measurements examined to assess the effectiveness of the device. This included analysis of brain activity, balance and behavior. Evaluations were completed at enrolment and again after the 12-week therapy concluded.
More than 700 potential subjects aged 5-17 applied to participate in the trial, with 83 recruited and 34 participants completing.
Critically, these positive results suggest that Mente Autism is uniquely positioned to target autism as a home-based neurofeedback tool, and clinical evidence from the trial will be used to support the NTI’s submission to the US Food and Drug Administration (FDA), which is targeted for the third quarter of calendar 2018.
NTI held a webinar to discuss the US clinical trial on 12 July 2018, which is available here
NTI onboards new Non-Executive Director
Following the retirement of Neurotech founder, Dr Adrian Attard Trevisan, as a Non-Executive Director in June, NTI has onboarded neuroscience expert, Dr David Cantor.
Cantor is a highly distinguished clinician, neuroscientist, program developer and a member of the NTI’s scientific advisory board, with a career spanning more than 40 years in the academic and clinical neuroscience sector.
He is CEO and Clinical Director of Mind and Motion Developmental Centers of Georgia, a multidisciplinary treatment facility providing a range of diagnostic and treatment services to children and adults seeking help with neurological disorders such as autism, ADHD, traumatic brain injury, and sensory processing disorders.
On top of that, Cantor is also the CEO and Managing Partner of BrainDx, an international software company that produces functional brain analytic software through computer assisted quantitative EEG (QEEG) reports and big database measures of brain development.
Moving forward
Promisingly, with its positive US clinical trial results now in hand, RGI’s next regulatory milestone will be obtaining the US FDA clearance for the Mente Autism device using a de-novo application process.
NTI expects to complete these elements and provide its submission to the FDA before the end of Q3. Depending on several factors, including the FDA's current backlog, benchmarks indicate the approval would take 9 - 12 months.
Business development & marketing activities a focus for H2 2018
Initial units of the next batch of Mente Autism devices are expected to be available this month, with the first shipment of devices expected in August. Pre-orders have been received from several of NTI’s existing distributors, who are initiating various marketing activities to coincide with the release of the Mente Autism clinical trial results.
Promosalute, Neurotech's Italian distribution partner, has also been active with a series of marketing activities including a targeted online marketing exercise and the opening of the first three neurofeedback centres throughout Italy.
Encouragingly, since the release of the US clinical trial results, NTI has seen a considerable surge in enquiries from potential distributors from other geographies, and management expects to broaden its reach with new distribution agreements through 2018 and 2019, with a focus on establishing a presence in the UK, France and Spain.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
